Last reviewed · How we verify
NCT03062163
Efficacy and Safety of Resveratrol and Lipoic Acid Transdermal Patch for Lipolysis in Overweight Volunteers
NA trial testing Resveratrol lipoic Acid in Lipolysis in 66 participants. Completed in 6 February 2017.
6 February 2017
Quick facts
| Lead sponsor | Chulalongkorn University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 66 |
| Start date | 23 January 2017 |
| Primary completion | 6 February 2017 |
| Estimated completion | 6 February 2017 |
| Sites | 1 location across Thailand |
Drugs / interventions tested
- Resveratrol lipoic Acid
- Placebo
Conditions studied
- Lipolysis — all drugs for Lipolysis →
Sponsor
Chulalongkorn University
Who can join
Adults 18 to 50, any sex, with Lipolysis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the lipolysis effect of resveratrol and lipoic acid transdermal patch in overweight volunteers
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Resveratrol for Weight Loss in Obesity: An Assessment of Randomized Control Trial Designs in ClinicalTrials.gov.
Hillsley A, Chin V, Li A, McLachlan CS. · · 2022 · cited 12× · PMID 35406038 · DOI 10.3390/nu14071424 -
The effects of alpha-lipoic acid transdermal patch for local subcutaneous fat reduction: A randomized, placebo-controlled, clinical trial in overweight volunteers.
Sooklert K, Thamakaison S, Nilyai S, Cherdchom S, et al · · 2024 · PMID 39678156 · DOI 10.1016/j.conctc.2024.101402
Verify or expand the search:
- PubMed search for NCT03062163
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lipolysis
Currently open trials in the same condition.
- NCT07426172 — Role of Elevated Lactate Levels on Lipid and Carbohydrate Metabolism. · NA · recruiting
Other Chulalongkorn University trials
Trials by the same sponsor.
- NCT07458659 — Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed/Refractory Multiple Myel · EARLY_PHASE1 · not yet recruiting
- NCT07346118 — Fluid Balance Guided by Modified Venous Excess Ultrasonography Versus Standard Care in Patients With Acute Kidney Injury · NA · not yet recruiting
- NCT07388862 — Comparison of Treatment Outcome of Pulpotomy With Versus Without Dental Operating Microscope in Carious Mature Permanent · EARLY_PHASE1 · not yet recruiting
- NCT07373977 — Comparison of Postoperative Pain After Pulpotomy Performed With Versus Without Dental Operating Microscope in Carious Ma · EARLY_PHASE1 · not yet recruiting
- NCT07078929 — Clinical Trial of CMD63 Chimeric Antigen Receptor T-cell (CAR T-cell) in Children With Acute Lymphoblastic Leukemia (ALL · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03062163 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chulalongkorn University
- Last refreshed: 23 February 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03062163.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing